Cargando…
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
BACKGROUND: This multicenter, open-label, single-arm phase II study [Niigata Lung Cancer Treatment Group (NLCTG) 1302] was conducted to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy for previously treated patients with advanced non-small cell...
Autores principales: | Shoji, Satoshi, Miura, Satoru, Watanabe, Satoshi, Ohtsubo, Aya, Nozaki, Koichiro, Saida, Yu, Ichikawa, Kosuke, Kondo, Rie, Tanaka, Tomohiro, Koyama, Kenichi, Tanaka, Hiroshi, Okajima, Masaaki, Abe, Tetsuya, Ota, Takeshi, Ishida, Takashi, Makino, Masato, Iwashima, Akira, Sato, Kazuhiro, Matsumoto, Naoya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359941/ https://www.ncbi.nlm.nih.gov/pubmed/35958345 http://dx.doi.org/10.21037/tlcr-22-89 |
Ejemplares similares
-
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022) -
Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019) -
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
por: Okajima, Masaaki, et al.
Publicado: (2021) -
Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020) -
The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
por: Fujisaki, Toshiya, et al.
Publicado: (2021)